<DOC>
	<DOCNO>NCT01799083</DOCNO>
	<brief_summary>Determine alone combination chemotherapy autologous cytokine induce killer cell effective safe treatment patient relapse and/or refractory solid tumor B Cell lymphoma .</brief_summary>
	<brief_title>Lower Dose Decitabine Based Therapy Patients With Refractory and/or Chemotherapy Resistant Solid Tumors B Cell Lymphomas</brief_title>
	<detailed_description>The purpose study determine whether low dose decitabine base therapy safe effectively control tumor progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Solid Tumor Histologically confirm advanced solid tumor 1 3 prior treatment regimen At least one site radiographically measurable disease ≥ 2 cm large dimension traditional computerized tomography ( CT ) scan technique ≥ 1 cm large dimension spiral CT scanning ( per RECIST criterion ) ; , Principal Investigator 's opinion , evaluable disease reliably consistently follow , subject may eligible upon approval Medical Monitor B Cell Lymphoma Histologically cytologically confirm B Cell Lymphoma . Patients must initial diagnosis B Cell NHL ( include follicular , small lymphocytic , lymphoplasmacytoid , marginal zone lymphoma ) , indolent disease transform aggressive subtype , previously describe patient may mantle cell lymphoma . Patients require received prior chemotherapy ( alone combine rituximab treatment ) consider refractory ( define response , progression within 6 month complete therapy ) intolerant continue rituximab treatment . Patients may receive maximum four prior unique chemotherapy regimen , include contraindicate autologous stemcell transplantation ( ASCT ) . For patient enroll expand dose group lymphoma , patient must measurable disease Disease Related Chemotherapy approve investigational anticancer therapeutic , include steroid therapy , within 3 week prior first dose 6 week antibody therapy Radiation therapy immunotherapy within 3 week prior first dose ( except antibody therapy , 6 week require ) ; localize radiation therapy within 1 week prior first dose Subjects prior brain metastasis permit , must complete treatment evidence active central nervous system ( CNS ) disease least 4 week prior first dose For lymphoma patient ; patient prior stem cell transplant therapy ( autologous SCT within prior 8 week ; allogeneic SCT within prior 16 week ) . Patients prior allogeneic SCT evidence moderatetosevere GVHD . Participation investigational therapeutic study within 3 week prior first dose Prior treatment decitabine Concurrent Conditions Major surgery within 3 week prior first dose Congestive heart failure ( New York Heart Association class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 3 month prior first dose Acute active infection require systemic antibiotic , antiviral , antifungal within 2 week prior first dose Known suspected HIV infection subject HIV seropositive Active hepatitis A , B , C infection Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose Ethical / Other Female subject pregnant lactate Any clinically significant psychiatric medical condition opinion Investigator could interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>B cell lymphoma</keyword>
</DOC>